PUBPAT wins HIV/AIDS drug reviews
p2pnet news | off topic:- Public Patent Foundation requests to review four key HIV/AIDS drug patents held by Gilead Sciences have been granted by the US Patent and Trademark Office, says PUBPAT.
“The U.S. Food and Drug Administration will not allow anyone other than Gilead distribute TDF in the United States because Gilead claims the four challenged patents give them the exclusive right to do so,” it says, going on:
In its March filings challenging the patents, PUBPAT submitted prior art that the Patent Office did not review before granting the patents to the Foster City, California, biopharmaceutical giant. PUBPAT also described in detail how the prior art invalidates the patents.
The Patent Office has now found that PUBPAT’s filings indeed raised “substantial questions” regarding the validity of each of the four Gilead Sciences patents. Having granted PUBPAT’s requests to review each of the patents, the Patent Office will now turn to deciding whether they deserve to exist or not.
The Gilead Sciences TDF patents challenged by PUBPAT now being reviewed by the Patent Office are US Patents No 5,922,695, 5,935,946, 5,977,089 and 6,043,230.
“Gilead has applied for similar patents on TDF in other countries throughout the world, including India, where they have received fierce opposition by non-profit AIDS patient groups,” adds PUBPAT.
Also See:
PUBPAT – Key HIV/AIDS drug patent is to be reviewed by the US Patent Office, July 18, 2007
Use free p2pnet newsfeeds for your site. It’s really easy!
Subscribe to p2pnet.net | | rss feed: http://p2pnet.net/p2p.rss | | Mobile – http://p2pnet.net/index-wml.php
Net access blocked by government restrictions? Use Psiphon from the Citizen Lab at the University of Toronto. Go here for details. Download here.
